Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13075-022-02818-6
PubMed Identifier: 35650639
Publication URI: http://europepmc.org/abstract/MED/35650639
Type: Journal Article/Review
Volume: 24
Parent Publication: Arthritis research & therapy
Issue: 1
ISSN: 1478-6354